Related Content
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- CVS partnership may drive down healthcare costs
- UnitedHealth: Cost of diabetes could be $3.35 trillion by 2020
- Bartell to cease filling Medicaid prescriptions at 15 locations
- FMAP extension: An investment and a money-saving venture
MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.
Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.
Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.
